The raised guidance and strong Q2 revenue validate AUCATZYL's commercial trajectory, while the credit facility removes near-term dilution risk. Watch for full Q2 results on August 11, 2026, and any updates on autoimmune program milestones that could trigger the additional $150M tranche. The high interest rate (SOFR + 7.25%) and warrant issuance are manageable given the revenue growth trajectory.
Price Chart
Executive Summary
Autolus Therapeutics raised FY2026 AUCATZYL net product revenue guidance to $140M-$150M (from $120M-$135M) and reported preliminary Q2 2026 AUCATZYL net product revenue of ~$45M, with gross margin improving from negative ~20% in H2 2025 to positive ~35% in H1 2026. The company also secured a $250M credit facility with Perceptive Advisors ($75M funded at close), extending cash runway into Q2 2028. The combination of strong commercial execution and non-dilutive capital provides a clear positive catalyst for the stock, though the high-cost debt and warrant issuance temper the upside.
Key Facts
- Preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million
- FY2026 AUCATZYL net product revenue guidance raised to $140-$150 million from $120-$135 million
- Gross margin improved from negative ~20% in H2 2025 to positive ~35% in H1 2026
- Entered into a $250 million senior credit facility with Perceptive Advisors; $75 million funded at close on July 30, 2026
- Additional $25 million available at Autolus' option for up to six months; up to $150 million more upon revenue milestones
- Credit facility is interest-only for five years at SOFR (floor 3.50%) + 7.25% per annum
- Issued warrant to Perceptive for 3.5 million ADSs at $1.9314 per ADS (125% of 30-day VWAP)
- Cash runway extended into Q2 2028 based on current operating plans and credit facility proceeds
- Q2 2026 AUCATZYL sales increased ~70% over Q1 2026 and >100% over Q2 2025
Financial Impact
FY2026 revenue guidance raised by $17.5M at midpoint to $145M; $75M non-dilutive capital raised at close with up to $250M total facility; gross margin swing from -20% to +35% represents a ~55 percentage point improvement
Risk Factors
- High interest rate on credit facility (SOFR + 7.25%) adds significant debt service cost
- Warrant issuance for 3.5 million ADSs creates potential future dilution
- Remaining $150M tranche contingent on revenue milestones which may not be achieved
- Gross margin of 35% still relatively low for a CAR-T product; further improvement needed for profitability
- Competition from other CAR-T therapies and alternative treatments for r/r B-ALL
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001730463-26-000112 |
| Document: autlex-991pr030826.htm | 0001730463-26-000112 |
| Document: 0001730463-26-000112-index-headers.html | 0001730463-26-000112 |
| Document: 0001730463-26-000112-index.html | 0001730463-26-000112 |
| Document: 0001730463-26-000112.txt | 0001730463-26-000112 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 12, 2026 20d ago | S-3 | $1.94 $1.94 | · 0.00% | ▼ −0.11% | $1.78 (−8.25%) |
Aug 11, 2026 7w ago | 8-K | $2.33 $2.29 | ▼ −1.72% | ▼ −1.31% | $1.78 (−23.61%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Jun 12, 2026 16w ago | Press Release | $1.56 $1.51 | ▼ −3.21% | ▼ −3.88% | $1.78 (+14.10%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.56 $1.53 | ▲ +1.92% | ▲ +2.36% | $1.78 (−14.10%) |
Jun 9, 2026 16w ago | 8-K | $1.46 $1.50 | ▼ −2.74% | ▼ −0.33% | $1.78 (−21.92%) |
May 21, 2026 19w ago | Press Release | $1.70 $1.84 | ▲ +8.24% | ▲ +6.58% | $1.78 (+4.71%) |
May 14, 2026 20w ago | 8-K | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
May 14, 2026 20w ago | Press Release | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access